Abstract: Described herein are methods of recellularizing an organ or tissue matrix.

Abstract: The disclosure relates, in certain aspects, to compounds that can be used to inhibit ?-lactamases, such as but not limited to OXA enzymes, such as but not limited to OXA-24, OXA-48, and/or OXA-58. In certain embodiments, these compounds can be used to inhibit activity of ?-lactamases in vitro and in vivo.

Abstract: Described herein are methods of recellularizing an organ or tissue matrix.

Abstract: The invention provides for methods and materials to decellularize an organ or portion thereof and to recellularize such a decellularized organ or portion thereof to thereby generate an organ or portion thereof.

Abstract: The invention provides for methods and materials to decellularize a solid organ and to recellularize such a decellularized organ to thereby generate a solid organ.

Abstract: The invention provides for methods and materials to decellularize a solid organ and to recellularize such a decellularized organ to thereby generate a solid organ.

Abstract: The invention provides for methods and materials to decellularize a solid organ and to recellularize such a decellularized organ to thereby generate a solid organ.

Abstract: Described herein are methods of recellularizing an organ or tissue matrix.

Abstract: Described herein are methods of recellularizing an organ or tissue matrix.

Abstract: The invention provides for methods and materials to decellularize a solid organ and to recellularize such a decellularized organ to thereby generate a solid organ.

Abstract: The invention provides for methods and materials to decellularize a solid organ and to recellularize such a decellularized organ to thereby generate a solid organ.

Abstract: The invention provides for methods and materials to decellularize a solid organ and to recellularize such a decellularized organ to thereby generate a solid organ.

Abstract: Described herein are methods of recellularizing an organ or tissue matrix.

Abstract: The invention provides for methods and materials to decellularize an organ or portion thereof and to recellularize such a decellularized organ or portion thereof to thereby generate an organ or portion thereof.

Abstract: The invention described herein provides systems and apparatuses for an initial preparation of an organ or tissue scaffold comprising an extracellular matrix, and subsequent recellularization of the scaffold to ultimately form a resultant artificial organ or tissue incorporating the natural and original extracellular matrix. The techniques and equipment of the invention collectively minimize scaffold collapse, compression or physical damage to the organ as well as afford the advantages of significant maintenance of the initial natural structural and biochemical attributes of the organ or tissue. The invention is particularly useful in organ and tissue transplantation and repair.

Abstract: The invention provides for methods and materials to decellularize a solid organ and to recellularize such a decellularized organ to thereby generate a solid organ.

Abstract: The invention provides for adult cardiac uncommitted progenitor cells (UPCs), methods of making such cells, and methods of using such cells in the treatment, repair and/or regeneration of damaged cardiac tissue.

Abstract: Devices and methods whereby therapeutic agents may be injected into distinct organ locations in a minimally invasive manner. Most preferably the devices and methods employ a video-assisted thorascopic system (VATS) to enable a physician in real time to visually identify a distinct organ location into which therapeutic agent is to be injected. In particularly preferred forms, devices are provided for injecting a therapeutic agent into a tissue site which include a proximal handle, and a tubular barrel distally extending from the handle. The barrel has an injection needle at a distal end thereof which is most preferably angled relative to the barrel's elongate axis. The internal space of the barrel is sized and configured to receive a cartridge containing a therapeutic agent to be injected into the tissue site.

Abstract: The present invention relates generally to stem/progenitor cells and, in particular, to therapeutic strategies based on the use of such cells to effect vascular rejuvenation and/or to serve as delivery vehicles.

Abstract: The present invention relates, in general, to Fas Ligand (FasL) and, in particular, to a method of immunoprotecting transplanted cells using an uncleavable form of FasL. The invention also relates to compounds and compositions suitable for use in such a method.